Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

SHE:301089 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020
Operating Revenue	411.61	831.98	777.81	500.26	513.09	384.68
Other Revenue	3.53	3.53	6.91	2.22	14.86	1.29
Revenue	415.14	835.51	784.72	502.48	527.94	385.96
Revenue Growth (YoY)	-62.53%	6.47%	56.17%	-4.82%	36.79%	-1.29%
Cost of Revenue	381.71	365.37	329.64	314.12	304.54	229.33
Gross Profit	33.42	470.14	455.08	188.36	223.4	156.63
Selling, General & Admin	79.75	101.65	107.5	75.61	57.33	56.22
Research & Development	45.22	51.25	31.02	20.97	18.82	15.52
Other Operating Expenses	13.97	13.02	11.77	6.79	6.15	6.3
Operating Expenses	133.25	170.4	147.28	104.45	82.46	77.09
Operating Income	-99.82	299.74	307.8	83.92	140.94	79.54
Interest Expense	-0.05	-0.34	-3.38	-9.13	-13.87	-14.14
Interest & Investment Income	7.83	9.86	10.64	2.41	2.47	2.54
Currency Exchange Gain (Loss)	0.68	0.68	1.5	-1.19	-1.23	-0.06
Other Non Operating Income (Expenses)	-4.01	-0.27	1.83	-1.82	-0.48	-0.95
EBT Excluding Unusual Items	-95.38	309.66	318.39	74.19	127.83	66.94
Gain (Loss) on Sale of Investments	0.24	0.55	0.16	0.62	-	-
Gain (Loss) on Sale of Assets	-	-	0.03	-	-0.37	0
Asset Writedown	-0.07	-4.22	-1.03	-0.3	-	-0.15
Other Unusual Items	21.22	10.54	7.73	3.53	7.98	3.58
Pretax Income	-73.98	316.53	325.27	78.04	135.44	70.37
Income Tax Expense	-1.21	73.46	38.73	12.33	22.64	9.12
Earnings From Continuing Operations	-72.77	243.07	286.54	65.71	112.8	61.25
Net Income	-72.77	243.07	286.54	65.71	112.8	61.25
Net Income to Common	-72.77	243.07	286.54	65.71	112.8	61.25
Net Income Growth	-	-15.17%	336.05%	-41.75%	84.16%	-3.11%
Shares Outstanding (Basic)	131	126	126	100	95	94
Shares Outstanding (Diluted)	131	126	126	100	95	94
Shares Change (YoY)	3.92%	-0.22%	26.78%	5.03%	0.59%	-0.13%
EPS (Basic)	-0.55	1.93	2.27	0.66	1.19	0.65
EPS (Diluted)	-0.55	1.93	2.27	0.66	1.19	0.65
EPS Growth	-	-14.98%	243.94%	-44.54%	83.08%	-2.99%
Free Cash Flow	10.43	-158.27	120.52	-54.53	45.88	10.17
Free Cash Flow Per Share	0.08	-1.26	0.95	-0.55	0.48	0.11
Dividend Per Share	0.250	0.250	0.400	0.100	-	-
Dividend Growth	-37.50%	-37.50%	300.00%	-	-	-
Gross Margin	8.05%	56.27%	57.99%	37.49%	42.32%	40.58%
Operating Margin	-24.05%	35.88%	39.22%	16.70%	26.70%	20.61%
Profit Margin	-17.53%	29.09%	36.51%	13.08%	21.37%	15.87%
Free Cash Flow Margin	2.51%	-18.94%	15.36%	-10.85%	8.69%	2.64%
EBITDA	-48.73	346.3	348.32	114.84	158.33	95.94
EBITDA Margin	-11.74%	41.45%	44.39%	22.85%	29.99%	24.86%
D&A For EBITDA	51.09	46.56	40.52	30.92	17.39	16.4
EBIT	-99.82	299.74	307.8	83.92	140.94	79.54
EBIT Margin	-24.05%	35.88%	39.22%	16.70%	26.70%	20.61%
Effective Tax Rate	-	23.21%	11.91%	15.80%	16.72%	12.96%
Revenue as Reported	415.14	835.51	784.72	502.48	527.94	385.96
Advertising Expenses	-	1.81	1.15	0.66	0.81	1.24

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.